Group 1: Business Operations - The company's plant protection business has reached a bottom in inventory reduction, and future operations are expected to stabilize [1] - The company maintains a long-term partnership with clients, focusing on a CDMO business model for the production of advanced intermediates [1] - The company plans to invest $200 million in the construction of its Malaysia base, with the first phase expected to be completed by the end of 2026 [4] Group 2: New Energy Sector - The company primarily sells LiFSI, cathode materials, and electrolyte products, with plans to strengthen existing products in 2026 [3] - The lithium hexafluorophosphate product is undergoing technical improvements, with commercialization expected in 2026 [3] - The company aims to expand its new energy product range and market presence, leveraging its R&D and production capabilities [3] Group 3: Pharmaceutical Business - The pharmaceutical sector has shown steady growth, with a focus on large clients and CDMO business models [5] - The company is actively expanding its client base and developing new projects in the pharmaceutical sector [5] - The company is investing in R&D to enhance its technical capabilities, exploring new areas such as amino acids and peptides [6] Group 4: Client Dependency and Market Strategy - The company acknowledges a high client concentration but emphasizes the importance of maintaining strong relationships with existing clients while seeking new ones [6][7] - The company believes that focusing on existing clients and expanding the customer base fosters mutual trust and sustainable cooperation [7] Group 5: Financial Outlook and Capital Expenditure - The company has no immediate plans for capital operations in the secondary market, focusing instead on investments in its coastal and Malaysian bases [7] - The net cash flow from operating activities for the first three quarters of 2025 is approximately 1 billion, sufficient to support planned capital expenditures [7] - Exchange rate gains and losses are expected to continue affecting net profits, with significant USD revenues and hedging activities in place [7]

Core Viewpoint - The company has experienced steady growth in its pharmaceutical business in recent years, driven by a focus on a major client strategy and a CDMO business model [1] Group 1: Business Strategy - The company has established partnerships with several leading global pharmaceutical enterprises and is actively expanding its client base to include strategic and high-viscosity clients [1] - The pharmaceutical division has formed stable commercial relationships with a number of high-quality domestic and international clients, with an expanding scope and depth of cooperation [1] Group 2: Product Pipeline and Future Growth - The company aligns its product pipeline with the business lines of its clients, primarily focusing on products under patent protection, which is expected to drive long-term growth in the pharmaceutical business as these products are promoted [1] - Future growth will focus on expanding mature businesses, including small molecule CDMO, starting materials, registered raw materials, GMP intermediates, and active pharmaceutical ingredients (APIs) [1] - The company aims to capture new projects from existing clients in small molecules and small nucleic acid CDMO, as well as new projects from new clients [1] - Significant investments will be made in emerging business development, including CDMO for peptide products, radiopharmaceuticals, animal health CDMO, generic drug intermediates, APIs, and cosmetic raw materials [1]

Core Viewpoint - The company, Lianhua Technology, aims to expand its mature business segments while investing in emerging areas, particularly in the CDMO (Contract Development and Manufacturing Organization) sector for small molecules and nucleic acids [1] Group 1: Business Expansion - The company plans to continue growing its mature businesses, including small molecule CDMO, starting materials, registered materials, GMP intermediates, and advanced raw materials [1] - It aims to capture new projects from existing clients and attract new clients in the small molecule and small nucleic acid CDMO sectors [1] Group 2: Investment in Emerging Areas - The company is heavily investing in the development of emerging businesses, including peptide CDMO, radiopharmaceutical-related CDMO, animal health CDMO, generic drug intermediates, APIs, and cosmetic raw materials [1] - This year, the company has focused on technological R&D in pharmaceutical products, expanding from traditional small molecules to amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides [1] Group 3: Service Capabilities - The team is enhancing client support for early clinical project transitions by providing diverse linker synthesis services required for ADC/PROTAC drug development [1] - The company has experience in delivering linker types from gram to hundred-gram levels and can design and optimize linker structures and synthesis routes based on client needs [1] - These new initiatives are expected to broaden the company's pharmaceutical CDMO service offerings and enable it to undertake more projects [1]

Group 1: Pharmaceutical Business Development - The company’s pharmaceutical business is rapidly developing, focusing on a large customer strategy primarily through the CDMO model, with ongoing efforts to attract strategic and high-viscosity clients [1] - The pharmaceutical division has established stable commercial relationships with several high-quality domestic and international clients, with an expanding scope of cooperation [1] - The company plans to continue growing its mature businesses, including small molecule CDMO, starting materials, and GMP intermediates, while also investing in emerging businesses such as peptide CDMO and radioactive drug-related CDMO [2] Group 2: Impact of Geopolitical Factors - Geopolitical issues have a limited direct impact on the company’s business but do affect client supply chain decisions [3] - The company views geopolitical challenges as an opportunity to enhance its global service capabilities by establishing overseas bases in the UK and Malaysia, creating a "multi-site supply, flexible delivery" solution [3] Group 3: Patent Expiry and Market Strategy - The expiry of certain agricultural product patents has a limited overall impact on the company, supported by its large customer strategy and CDMO model [4] - Long-term framework agreements with core clients ensure stability in supply, even for products whose patents have expired [4] - The company is optimizing production and reducing costs to enhance market competitiveness while focusing on new patented products through initiatives like the Malaysian base [4] Group 4: New Energy Business Outlook - The company currently focuses on sales of LiFSI and electrolyte products, with ongoing technical improvements on lithium hexafluorophosphate projects [5] - The new energy business is expected to achieve significant revenue breakthroughs in 2025 [5]